Concepedia

Author

Jan J. Molenaar

Princess Máxima CenterORCID

Also Known As

J J Molenaar, J Molenaar, J. J. Molenaar, J. Molenaar, J.J. Molenaar, Jan J. Molenaar, Jan J Molenaar, Jan J. Molenaar, Jan Jasper Molenaar, Jan Molenaar

292

Publications

11.2K

Citations

51

H-Index

90

Concepts

All Affiliations

Princess Máxima CenterUniversity of AmsterdamAmsterdam UMC Location University of AmsterdamEmma KinderziekenhuisHeidelberg University
JJ

About

Jan J. Molenaar is an author at Princess Máxima Center specializing in medicine, cell biology, and tumor biology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

26

34

4.5K

2

Natural Sciences

3

3

143

3

Engineering

2

2

36

4

Health Sciences

2

2

63

5

Biochemistry

1

1

11

Jan J. Molenaar

×

83

Publications

8K

Citations

43

H-Index

YearCitations

Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes

Jan J. Molenaar, Jan Köster, Danny A. Zwijnenburg,

Nature

2012

870

Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations

Tobias Rausch, David Jones, Marc Zapatka,

Cell

2012

857

Neuroblastoma is composed of two super-enhancer-associated differentiation states

Tim van Groningen, Jan Köster, Linda J. Valentijn,

Nature Genetics

2017

554

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

Thomas F. Eleveld, Derek A. Oldridge, Virginie Bernard,

Nature Genetics

2015

543

LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression

Jan J. Molenaar, Raquel Domingo-Fernandéz, Marli E. Ebus,

Nature Genetics

2012

384

TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors

Linda J. Valentijn, Jan Köster, Danny A. Zwijnenburg,

Nature Genetics

2015

375

An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity

Camilla Calandrini, Frans Schutgens, Rurika Oka,

Nature Communications

2020

301

The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets

Cornelis M. van Tilburg, Elke Pfaff, Kristian W. Pajtler,

Cancer Discovery

2021

236

Functional MYCN signature predicts outcome of neuroblastoma irrespective of <i>MYCN</i> amplification

Linda J. Valentijn, Jan Köster, Franciska Haneveld,

Proceedings of the National Academy of Sciences

2012

231

Cyclin D1 and CDK4 Activity Contribute to the Undifferentiated Phenotype in Neuroblastoma

Jan J. Molenaar, Marli E. Ebus, Jan Köster,

Cancer Research

2008

170

Page 1